The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human macrophages

Genes and Immunity

Volumn 15, Issue 7, 2014, Pages 477-486

  Ottow, M K ^a   Klaver, E J ^a   Van Der Pouw Kraan, T C T M ^a   Heijnen, P D ^a   Laan, L C ^a   Kringel, H ^b   Vogel, D Y S ^a   Dijkstra, C D ^a   Kooij, G ^a   Van Die, I ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CCL1 CHEMOKINE; COLONY STIMULATING FACTOR 1; CXCL9 CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; HELMINTH PROTEIN; PURINERGIC P2X7 RECEPTOR; TLR4 PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRICHURIS SUIS; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; TRICHURIS;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL1; CHEMOKINE CXCL9; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HELMINTH PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-12 SUBUNIT P40; MACROPHAGES; RECEPTORS, PURINERGIC P2X7; TOLL-LIKE RECEPTOR 4; TRICHURIS;

EID: 84908230313     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2014.38     Document Type: Article

References (43)

1. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911-920.
2. Zaccone P, Cooke A. Vaccine against autoimmune disease: can helminths or their products provide a therapy? Curr Opin Immunol 2013; 25: 418-423.
3. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-1260.
4. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2009; 15: 128-133.
5. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006; 67: 2085-2086.
6. Bager P, Arnved J, Ronborg S, Wohlfahrt J, Poulsen LK, Westergaard T et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010; 125: 123-30 e1-3.
7. Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 2010; 40: 299-306.
8. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007; 61: 97-108.
9. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 2011; 233: 6-11.
10. Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 2011; 17: 743-754.
11. Kuijk LM, Klaver EJ, Kooij G, van der Pol SM, Heijnen P, Bruijns SC et al. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol Immunol 2012; 51: 210-218.
12. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev 2011; 11: 723-737.
13. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev 2008; 8: 958-969.
14. Elliott DE, Weinstock JV. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci 2012; 1247: 83-96.
15. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 2013; 10: 35.
16. Klaver EJ, Kuijk LM, Laan LC, Kringel H, van Vliet SJ, Bouma G et al. Trichuris suisinduced modulation of human dendritic cell function is glycan-mediated. Int J Parasitol 2013; 43: 191-200.
17. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH. Phenotypic and functional profiling of human proinflammatory type-1 and antiinflammatory type-2 macrophages in response to microbial antigens and IFNgamma-and CD40L-mediated costimulation. J Leukoc Biol 2006; 79: 285-293.
18. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-567.
19. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 2001; 194: 873-882.
20. Schlee M. Master sensors of pathogenic RNA-RIG-I like receptors. Immunobiology 2013; 218: 1322-1335.
21. Gouwy M, Struyf S, Leutenez L, Portner N, Sozzani S, Van Damme J. Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells. Immunobiology 2014; 219: 218-229.
22. Donnelly-Roberts DL, Jarvis MF. Discovery of P2-7 receptor-selective antagonists offers new insights into P2-7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 2007; 151: 571-579.
23. Hiemstra IH, Klaver EJ, Vrijland K, Kringel H, Andreasen A, Bouma G et al. Excreted/secreted Trichuris suis products reduce barrier function and suppress inflammatory cytokine production of intestinal epithelial cells. Mol Immunol 2014; 60: 1-7.
24. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 2011; 17: 557-566.
25. Diaz A, Allen JE. Mapping immune response profiles: the emerging scenario from helminth immunology. Eur J Immunol 2007; 37: 3319-3326.
26. Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012; 375: 196-206.
27. Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Paulig A et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998; 51: 753-758.
28. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009; 9: 319-321.
29. Shin T, Kang B, Tanuma N, Matsumoto Y, Wie M, Ahn M et al. Intrathecal administration of endothelin-1 receptor antagonist ameliorates autoimmune encephalomyelitis in Lewis rats. NeuroReport 2001; 12: 1465-1468.
30. Cunningham ME, Huribal M, Bala RJ, McMillen MA. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997; 25: 958-964.
31. Majetschak M. Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J Leukoc Biol 2011; 89: 205-219.
32. Cesaro A, Brest P, Hofman V, Hebuterne X, Wildman S, Ferrua B et al. Amplification loop of the inflammatory process is induced by P27R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am J Physiol 2010; 299: G32-G42.
33. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C et al. COX-2, CB2 and P27-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 6: 12.
34. Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 2009; 207: 101-106.
35. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF. The cytokine IL-1beta transiently enhances P2 7 receptor expression and function in human astrocytes. Glia 2005; 49: 245-258.
36. Ambrosini E, Remoli ME, Giacomini E, Rosicarelli B, Serafini B, Lande R et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005; 64: 706-715.
37. Wagner DR, Kubota T, Sanders VJ, McTiernan CF, Feldman AM. Differential regulation of cardiac expression of IL-6 and TNF-alpha by A2-and A3-adenosine receptors. Am J Physiol 1999; 276(6 Pt 2): H2141-H2147.
38. Zhang J, Tachado SD, Patel N, Zhu J, Imrich A, Manfruelli P et al. Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro. J Leukoc Biol 2005; 78: 665-674.
39. Fleming JO. Helminth therapy and multiple sclerosis. Int J Parasitol 2013; 43: 259-274.
40. Fabriek BO, Van Haastert ES, Galea I, Polfliet MM, Dopp ED, Van Den Heuvel MM et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005; 51: 297-305.
41. Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL et al. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 2009; 46: 177-185.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
43. Kooij G, Mizee MR, van Horssen J, Reijerkerk A, Witte ME, Drexhage JA et al. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 2011; 134(Pt 2): 555-570.